Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$453M |
| 2 |
CELG
Celgene Corp
CELG
|
+$391M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$389M |
| 4 |
GE Aerospace
GE
|
+$378M |
| 5 |
Johnson & Johnson
JNJ
|
+$356M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$307M |
| 2 |
Costco
COST
|
+$279M |
| 3 |
Lowe's Companies
LOW
|
+$273M |
| 4 |
Microsoft
MSFT
|
+$230M |
| 5 |
Chevron
CVX
|
+$225M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.59% |
| 2 | Technology | 14.11% |
| 3 | Financials | 10.92% |
| 4 | Consumer Discretionary | 9.85% |
| 5 | Real Estate | 7.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
401
Nike
NKE
$60.3B
| $62.7M | 0.06% |
747,400
+116,886
| +19% | +$9.84M |
|
402
Banco de Chile
BCH
$20.5B
| $62.4M | 0.05% |
2,101,975
+20,519
| +1% | +$596K |
|
403
Corcept Therapeutics
CORT
$12.2B
| $62.3M | 0.05% |
5,590,509
+532,700
| +11% | +$5.94M |
|
|
ARRY
404
DELISTED
Array Biopharma Inc
ARRY
| $62.3M | 0.05% |
1,344,652
+1,047,084
| +352% | +$29.4M |
|
405
Visa
V
$670B
| $62.2M | 0.05% |
358,522
-1,176,625
| -77% | -$193M |
|
406
RELX
RELX
$60.3B
| $61.6M | 0.05% |
2,521,900
-31,800
| -1% | -$732K |
|
|
MIC
407
DELISTED
Macquarie Infrastructure Holdings, LLC
MIC
| $61.3M | 0.05% |
1,511,700
+357,200
| +31% | +$14.6M |
|
408
WD-40
WDFC
$3.11B
| $61.1M | 0.05% |
384,238
-119,400
| -24% | -$19.6M |
|
|
EA
409
DELISTED
Electronic Arts
EA
| $60.4M | 0.05% |
+596,164
| New | +$56.8M |
|
410
Insperity
NSP
$1.93B
| $60.4M | 0.05% |
494,246
-188,000
| -28% | -$22.7M |
|
|
SEE
411
DELISTED
Sealed Air
SEE
| $60.2M | 0.05% |
1,408,334
+271,125
| +24% | +$11.9M |
|
412
Intercontinental Exchange
ICE
$85B
| $60M | 0.05% |
697,890
+224,900
| +48% | +$18.4M |
|
413
Peabody Energy
BTU
$2.95B
| $59.9M | 0.05% |
2,485,145
+411,200
| +20% | +$10.8M |
|
414
Ovintiv
OVV
$17.5B
| $59.8M | 0.05% |
2,333,240
+2,316,320
| +13,690% | +$72.2M |
|
415
Pinduoduo
PDD
$126B
| $59.4M | 0.05% |
+2,880,474
| New | +$62.4M |
|
416
Morgan Stanley
MS
$344B
| $59.3M | 0.05% |
+1,354,100
| New | +$60.4M |
|
417
Progress Software
PRGS
$1.76B
| $59.3M | 0.05% |
1,359,711
+40,185
| +3% | +$1.74M |
|
418
Shenandoah Telecom
SHEN
$731M
| $59.2M | 0.05% |
1,537,600
+68,800
| +5% | +$2.85M |
|
419
Viavi Solutions
VIAV
$10.5B
| $59M | 0.05% |
4,442,088
+1,230,200
| +38% | +$15.9M |
|
420
Enova International
ENVA
$6.46B
| $58.9M | 0.05% |
2,554,294
-32,700
| -1% | -$783K |
|
421
UBS Group
UBS
$177B
| $58.8M | 0.05% |
4,960,600
+3,256,300
| +191% | +$39.9M |
|
422
Iridium Communications
IRDM
$5.24B
| $58.8M | 0.05% |
2,526,999
-337,500
| -12% | -$8.4M |
|
|
LM
423
DELISTED
Legg Mason, Inc.
LM
| $58.8M | 0.05% |
1,535,300
+103,700
| +7% | +$3.58M |
|
|
BRSS
424
DELISTED
Global Brass & Copper Hldgs, Inc
BRSS
| $58.5M | 0.05% |
1,337,300
+38,400
| +3% | +$1.63M |
|
425
DuPont de Nemours
DD
$19.3B
| $58.4M | 0.05% |
+619,618
| New | +$74M |
|
Similar funds
Jim Simons's Q2 2019 Portfolio in Review
As of Q2 2019, Jim Simons held 3,913 positions worth $114B, up 3.3% from $110B the previous quarter. Its ten largest holdings account for 9.1% of the portfolio.
Jim Simons's Q2 2019 filing shows 495 new, 1,847 increased, 1,145 reduced and 397 closed positions. Its largest new stake was Apple: 9,290,160 shares worth $460M. The largest sale was UnitedHealth, an estimated $307M.
By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 16% a quarter earlier, followed by Technology and Financials.
- Jim Simons's largest Q2 2019 buy was Apple: 9,290,160 shares worth $460M.
- Jim Simons added most to Celgene Corp in Q2 2019, an estimated $391M increase.
- Jim Simons's biggest Q2 2019 reduction was Microsoft, cutting an estimated $230M.
- Jim Simons fully exited UnitedHealth in Q2 2019, selling an estimated $307M.
- Jim Simons's ten largest holdings make up 9.1% of its $114B portfolio in Q2 2019.
- Jim Simons opened 495 new positions and closed 397 in Q2 2019.
- Jim Simons's portfolio value rose 3.3% quarter-over-quarter to $114B.
Based on Renaissance Technologies's 13F filing for Q2 2019, filed 12 Aug 2019.